BiotechTube
Augment Biologics

Augment Biologics

Salt Lake City, United States· Est.
augmentbiologics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Augment Biologics is a private, pre-clinical stage biotech founded in 2016, headquartered in Salt Lake City, UT, with an additional presence in San Francisco, CA. The company has developed GlycoTemplating, an AI-guided platform that represents a foundational shift in glycoengineering by allowing the precise, genetic encoding of glycans into biologics, turning glycosylation from a manufacturing variable into a programmable design feature. This approach aims to overcome the major limitations of current glycoengineering methods, with the goal of creating best-in-class therapeutics with enhanced efficacy, safety, and manufacturability. Augment is currently applying its platform to internal drug discovery programs while likely exploring partnership opportunities.

AI / Machine Learning

Technology Platform

GlycoTemplating: An AI-guided platform that enables the site-specific encoding of glycans directly into the primary protein sequence of biologics, allowing for rational design of drug properties including efficacy, safety, and manufacturability.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The platform addresses a fundamental challenge in biologics development, offering potential improvements to hundreds of existing glycosylated drugs and enabling new classes of therapeutics.
Its applicability extends from antibodies and proteins to emerging modalities like RNA therapeutics and vaccines, tapping into massive and growing markets.

Risk Factors

The core scientific risk is that the AI platform may not accurately predict or control complex glycosylation in all biological contexts.
As a pre-revenue platform company, it faces significant funding and execution risks, alongside competition from established glycoengineering methods and potential new entrants.

Competitive Landscape

Competition includes in-house glycoengineering efforts at large biopharma firms and alternative technological approaches from other biotechs, such as cell line engineering, enzymatic remodeling, and synthetic chemistry. Augment's differentiation lies in its AI-driven, sequence-based design approach that aims to be predictable and platform-agnostic from the start of development.

More companies in Biologics / Biosimilars →More companies in United States →